Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Danni LiDepartment of Lab Medicine Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-0608-2831
Binchong AnDepartment of Lab Medicine Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID 0009-0004-9935-4008
Lu MenDepartment of Lab Medicine Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID 0009-0005-9408-5248
Matthew GlittenbergSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.ORCID 0009-0002-9152-4637
Pamela L LutseySchool of Public Health, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-1572-1340
Michelle M MielkeDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA.ORCID 0000-0001-7177-1185
Fang YuEdson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA.ORCID 0000-0002-9399-1987
Ron C HoogeveenDivision of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0003-2399-4653
Rebecca GottesmanStroke, Cognition, and Neuroepidemiology Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.ORCID 0000-0002-9504-1256
Lin ZhangSchool of Public Health, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0002-0003-6084
Michelle MeyerGillings School of Global Public Health, Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kevin SullivanDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.ORCID 0000-0001-9147-0988
Nicole ZantekDepartment of Lab Medicine Pathology, University of Minnesota, Minneapolis, MN, USA.ORCID 0000-0001-5776-6400
Alvaro AlonsoDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID 0000-0002-2225-8323
Keenan A WalkerMultimodal Imaging of Neurodegenerative Disease (MIND) Unit, National Institute of Aging, Intramural Research Program, Baltimore, MD, USA.ORCID 0000-0002-5989-9853
Funding
ARIC Neurocognitive Study (ARIC-NCS) Renewal 2023-2028U01HL096812 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI JOSEF CORESH, THOMAS H MOSLEY · 2010 to 2026
$65.7M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7M
ARIC Neurocognitive Study (ARIC-NCS) Renewal 2 of 5U01HL096917 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI MOSLEY, THOMAS H · 2010 to 2018
$11.9M
ARIC Neurocognitive Study (ARIC-NCS) Renewal UNC 4 of 5U01HL096899 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J · 2010 to 2018
$7.5M
ARIC Neurocognitive Study (ARIC-NCS)U01HL096902 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2010 to 2018
$7.4M
The ARIC-PET Amyloid Imaging StudyR01AG040282 · NIA · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF, SPIRA, ADAM PETER · 2011 to 2021
$7.1M
ARIC Neurocognitive Study (ARIC-NCS) Renewal 4 of 5U01HL096814 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HUGHES, TIMOTHY M., WAGENKNECHT, LYNNE E · 2010 to 2018
$6.5M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00003 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA L. · 2022 to 2025
$5.1M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2022 to 2025
$5.0M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00004 · NHLBI · UNIVERSITY OF MISSISSIPPI MED CTR · PI WINDHAM, BEVERLY GWEN · 2022 to 2025
$4.8M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00002 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI ARGANI, PEDRAM · 2022 to 2025
$4.7M
Profiling Cardiovascular Events and Biomarkers in the Very Old to Improve Personalized Approaches for the Prevention of Cardiac and Vascular DiseaseR01HL134320 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI BALLANTYNE, CHRISTIE MITCHELL, SELVIN, ELIZABETH · 2016 to 2019
backgroundHigh-density lipoprotein (HDL) modulates the blood-brain barrier and cerebrovascular integrity, likely influencing the risk of Alzheimer's disease (AD), neurodegeneration, and cognitive decline.
objectiveThis study aims to identify HDL protein cargo associated with brain amyloid deposition and brain volume in regions vulnerable to AD pathology in older adults.
methodsHDL was separated from the plasma of 65 non-demented participants of the Atherosclerosis Risk in Communities (ARIC) study using a fast protein liquid chromatography method. HDL cargo proteins were measured using a label-free, untargeted proteomic method based on mass spectrometry and data-independent acquisition. Linear regression with multiple imputations assessed the associations between each HDL cargo protein (log2-transformed) and brain amyloid deposition or temporal-parietal meta-ROI volume, adjusting for covariates.
resultsThe mean (SD) age of the participants was 76.3 (5.4) years old, 53.8% (35/65) female, 30.8% (20/65) black, and 28.1% (18/64, 1 missing)
conclusionsThis study suggests that HDL cargo proteins associated with temporal-parietal meta-ROI volume are involved in complement and coagulation pathways.
Indexed as
AtherosclerosisBrainLipoproteins, HDLAgedAged, 80 and overAlzheimer DiseaseFemaleHumansMaleOrgan SizeProteomicsLipoproteins, HDLAlzheimer's diseasebrain amyloid depositionbrain volumeHDL protein cargohigh-density lipoprotein (HDL)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
The association of high-density lipoprotein cargo proteins with brain volume in older adults in the Atherosclerosis Risk in Communities (ARIC). · full record | Socratic